Heart failure, with 42 medicines currently in development, is the leading area for new treatments of cardiovascular disease, according to Pharmaceutical Research and Manufacturers of America.
One of those 42 treatments is “a nonviral gene therapy that targets a tissue repair and regeneration pathway in the body,” PhRMA noted. A total of 200 medicines, including those for lipid disorders and hypertension, were either in clinical trials or undergoing regulatory review as of Jan. 24, 2018, the group reported. Some treatments are being considered for more than one condition.
Other cardiovascular conditions with considerable research interest include stroke, with 23 medicines in development, and coronary artery disease, with 12 treatments in the development pipeline. One new treatment for stroke combines a human activated protein C and human stem cells, and a bromodomain and extraterminal (BET) protein inhibitor is now in clinical trials for coronary artery disease, type 2 diabetes, and low HDL cholesterol, according to PhRMA.
rfranki@frontlinemedcom.com
Heart failure, with 42 medicines currently in development, is the leading area for new treatments of cardiovascular disease, according to Pharmaceutical Research and Manufacturers of America.
One of those 42 treatments is “a nonviral gene therapy that targets a tissue repair and regeneration pathway in the body,” PhRMA noted. A total of 200 medicines, including those for lipid disorders and hypertension, were either in clinical trials or undergoing regulatory review as of Jan. 24, 2018, the group reported. Some treatments are being considered for more than one condition.
Other cardiovascular conditions with considerable research interest include stroke, with 23 medicines in development, and coronary artery disease, with 12 treatments in the development pipeline. One new treatment for stroke combines a human activated protein C and human stem cells, and a bromodomain and extraterminal (BET) protein inhibitor is now in clinical trials for coronary artery disease, type 2 diabetes, and low HDL cholesterol, according to PhRMA.
rfranki@frontlinemedcom.com
Heart failure, with 42 medicines currently in development, is the leading area for new treatments of cardiovascular disease, according to Pharmaceutical Research and Manufacturers of America.
One of those 42 treatments is “a nonviral gene therapy that targets a tissue repair and regeneration pathway in the body,” PhRMA noted. A total of 200 medicines, including those for lipid disorders and hypertension, were either in clinical trials or undergoing regulatory review as of Jan. 24, 2018, the group reported. Some treatments are being considered for more than one condition.
Other cardiovascular conditions with considerable research interest include stroke, with 23 medicines in development, and coronary artery disease, with 12 treatments in the development pipeline. One new treatment for stroke combines a human activated protein C and human stem cells, and a bromodomain and extraterminal (BET) protein inhibitor is now in clinical trials for coronary artery disease, type 2 diabetes, and low HDL cholesterol, according to PhRMA.
rfranki@frontlinemedcom.com
Content Gating
No Gating (article Unlocked/Free)
